Monitoring.
(c) For facilities that provide reclaimed
water for use in open cooling towers, the permittee shall sample the reclaimed
water for Cryptosporidium and Giardia. The following requirements shall be met:
1. Sampling shall be conducted at one time
during each two-year period. Intervals between sampling shall not exceed two
years. This sampling frequency is independent of the treatment plant's
capacity. The sample results shall be submitted to the Department on or before
November 28 of each even numbered year using Form
62-610.300(3)(a)
4., Pathogen Monitoring, (adopted and incorporated by reference in subparagraph
62-610.300(3)(a)
4., F.A.C., effective August 8, 2021,
http://www.flrules.org/Gateway/reference.asp?No=Ref-13373).
2. Samples shall be taken from at a point
immediately following the disinfection process.
3. Samples shall be taken during peak flow
periods between the months of August and October.
4. If the wastewater treatment facility uses
chlorination for disinfection, samples collected for analysis of Giardia and
Cryptosporidium shall be dechlorinated.
5. A grab sample for TSS shall be taken such
that it is representative of the water leaving the filters at the treatment
facility during the period when pathogen samples are taken. In addition, the
permittee shall record the lowest total residual chlorine observed during the
period when pathogen samples are collected.
6. EPA Method 1623.1, (adopted and
incorporated by reference in subsection
62-610.100(7),
F.A.C., effective August 8, 2021,
http://www.flrules.org/Gateway/reference.asp?No=Ref-133821),
or other approved methods in accordance with Rule
62-160.330, F.A.C., for
reclaimed water or nonpotable waters, adjusted appropriately to accommodate the
detection limit requirements, shall be used. Methods previously allowed for
EPA's ICR shall not be used. The full requirements of the approved method,
including quality assurance and quality control, are to be met. Quality
assurance and sampling requirements in Chapter 62-160, F.A.C., shall apply.
Two concentrations of Giardia and Cryptosporidium shall be
recorded on Part III of Form
62-610.300(3)(a)
4., Pathogen Monitoring, (adopted and incorporated by reference in subparagraph
62-610.300(3)(a)
4., F.A.C., effective August 8, 2021,
http://www.flrules.org/Gateway/reference.asp?No=Ref-13373).
b. Potentially viable cysts and oocysts shall
be enumerated using the DAPI staining technique contained in EPA Method 1623.1,
(adopted and incorporated by reference in subsection
62-610.100(7),
F.A.C., effective August 8, 2021,
http://www.flrules.org/Gateway/reference.asp?No=Ref-13382),
or similar enumeration techniques included in other approved methods in
accordance with Rule
62-160.330, F.A.C. Cysts and
oocysts that are stained DAPI positive or show internal structure by D.I.C.
shall be considered as being potentially viable. If the laboratory reports
separate values for DAPI positive and for cysts or oocysts having internal
structure, the larger of the two concentrations will be reported as being
potentially viable.
7. If
the number of potentially viable cysts of Giardia reported exceeds 5 per 100
liters or oocysts of Cryptosporidium reported exceeds 22 per 100 liters, a
subsequent sample shall be taken and analyzed using EPA Method 1623.1, (adopted
and incorporated by reference in subsection
62-610.100(7),
F.A.C., effective August 8, 2021,
http://www.flrules.org/Gateway/reference.asp?No=Ref-13382),
or other approved methods in accordance with Rule
62-160.330, F.A.C. This
subsequent sample shall be collected within 90 days of the date the initial
sample was taken, analyzed for both Giardia and Cryptosporidium, and the
results of the subsequent analysis shall be submitted to the department within
60 days of sample collection using Form
62-610.300(3)(a)
4., Pathogen Monitoring, (adopted and incorporated by reference in subparagraph
62-610.300(3)(a)
4., F.A.C., effective August 8, 2021,
http://www.flrules.org/Gateway/reference.asp?No=Ref-13373).